James Brorson to Platelet Aggregation Inhibitors
This is a "connection" page, showing publications James Brorson has written about Platelet Aggregation Inhibitors.
Connection Strength
1.655
-
Statin initiation and early stroke recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial (POINT) trial population. J Stroke Cerebrovasc Dis. 2025 Jul; 34(7):108349.
Score: 0.803
-
Outcomes of Patients With Embolic Stroke of Undetermined Source Treated With Antiplatelet Agents or Anticoagulation: A Multicenter Cohort Study. Neurology. 2025 Aug 12; 105(3):e213876.
Score: 0.203
-
Vulnerable and Stabilized States After Cerebral Ischemic Events: Implications of Kinetic Modeling in the SOCRATES, POINT, and THALES Trials. Neurology. 2023 11 27; 101(22):e2205-e2214.
Score: 0.181
-
Predictors of very early stroke recurrence in the POINT trial population. BMC Neurol. 2022 May 14; 22(1):177.
Score: 0.163
-
Two-State Kinetic Model of Rates of Stroke Recurrence in the POINT Study Population. Stroke. 2021 04; 52(4):1446-1449.
Score: 0.150
-
Ipsilateral Nonstenotic Carotid Disease in Minor Ischemic Stroke: an Exploratory Analysis of The POINT Randomized Clinical Trial. J Stroke Cerebrovasc Dis. 2020 Nov; 29(11):105115.
Score: 0.144
-
Transcatheter closure of patent foramen ovale in patients with paradoxical embolism: intermediate-term risk of recurrent neurological events. Catheter Cardiovasc Interv. 2002 Feb; 55(2):189-94.
Score: 0.010